Navigation Links
ULURU Inc. Announces Approval to Market Altrazeal® in Australia
Date:2/23/2012

ADDISON, Texas, Feb. 23, 2012 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU),announced today that an Australian Register of Therapeutic Goods Certificate has been issued by the Therapeutic Goods Administration approving the marketing of Altrazeal® in Australia.

Commenting on the approval in Australia, Kerry P. Gray, President and CEO of ULURU, stated, "This is another important milestone in the worldwide commercialization of Altrazeal®.  Strategically this is an important market as the world's largest wound research program is currently being conducted at the Wound Management Innovation Cooperation Research Centre in Australia.  This centre's focus is the development of clinically and cost effective treatment regimens for the management of chronic wounds.  Gaining the support of this influential group could have significant global implications for the marketing of Altrazeal®.  It is anticipated that the initial Altrazeal® orders for Australia will occur in the next thirty days.  Also, marketing approval in New Zealand is anticipated to occur in the next thirty days."

The timing of this approval is beneficial as the major Australian wound care meeting, the Australian Wound Management Association Conference, will be held in Sydney, Australia on March 18-21, 2012.  It is anticipated that over 1,000 delegates from Australia and New Zealand will be attending this conference.  The conference will enable pre-marketing launch activities to be conducted and provide maximum exposure for Altrazeal® to the most important wound treatment healthcare professionals from both countries. 

In Australia and New Zealand approximately 2.5% of the population, or 700,000 patients, suffer from chronic wounds, with 80% of these wounds caused by cardiovascular disease, endocrine disorders (including diabetes), and infection.  With the increase in cardiovascular disease, obesity, and the aging population, it is anticipated that the wound care market will double in size over the next five to seven years and the cost of treating chronic wounds will exceed $1.0 billion annually.

Mr. Gray continued, "The Australian state government's strategic initiatives in wound care are focused on cost effective clinical endpoints and patient health and wellbeing.  The pharmaco-economic benefits offered by Altrazeal® could enable rapid market penetration in the Australian market."

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal® will be a major competitor in the wound care market, anticipated product launches in Australia and New Zealand, the cost effectiveness and cost savings of Altrazeal® in healing chronic wounds, the size of the wound care market and the cost of treating chronic wounds in Australia and New Zealand, the world's largest wound research program is currently being conducted at the Wound Management Innovation Cooperation Research Centre in Australia, Altrazeal's clinical and economic advantages, and Altrazeal's ability to penetrate the Australian wound care market, and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):